Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-Xa assays.

Andreas Hillarp; Kerstin M Gustafsson; Lars Faxälv; Karin Strandberg; Fariba Baghaei; Inger Fagerberg Blixter; Maria Berndtsson; Tomas L Lindahl

doi:10.1111/jth.12649

Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-Xa assays.

Andreas Hillarp, Kerstin M Gustafsson, Lars Faxälv, Karin Strandberg, Fariba Baghaei, Inger Fagerberg Blixter, Maria Berndtsson, Tomas L Lindahl

Clinical Chemistry, Malmö

Research output: Contribution to journal › Article › peer-review

Abstract

Apixaban is an oral direct factor Xa inhibitor developed for prophylaxis and treatment of thromboembolic disorders. Laboratory monitoring is not necessary, but the effects on common coagulation reagents and assays are clinically valuable information.

Original language	English
Pages (from-to)	1545-1553
Journal	Journal of Thrombosis and Haemostasis
Volume	12
Issue number	9
DOIs	https://doi.org/10.1111/jth.12649
Publication status	Published - 2014

Subject classification (UKÄ)

Cardiac and Cardiovascular Systems

Access to Document

10.1111/jth.12649

http://www.ncbi.nlm.nih.gov/pubmed/24965851?dopt=Abstract

Cite this

@article{150f50336a274ea681f8e95b3b964112,

title = "Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-Xa assays.",

abstract = "Apixaban is an oral direct factor Xa inhibitor developed for prophylaxis and treatment of thromboembolic disorders. Laboratory monitoring is not necessary, but the effects on common coagulation reagents and assays are clinically valuable information.",

author = "Andreas Hillarp and Gustafsson, {Kerstin M} and Lars Fax{\"a}lv and Karin Strandberg and Fariba Baghaei and {Fagerberg Blixter}, Inger and Maria Berndtsson and Lindahl, {Tomas L}",

year = "2014",

doi = "10.1111/jth.12649",

language = "English",

volume = "12",

pages = "1545--1553",

journal = "Journal of Thrombosis and Haemostasis",

issn = "1538-7933",

publisher = "Elsevier",

number = "9",

}

TY - JOUR

T1 - Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-Xa assays.

AU - Hillarp, Andreas

AU - Gustafsson, Kerstin M

AU - Faxälv, Lars

AU - Strandberg, Karin

AU - Baghaei, Fariba

AU - Fagerberg Blixter, Inger

AU - Berndtsson, Maria

AU - Lindahl, Tomas L

PY - 2014

Y1 - 2014

N2 - Apixaban is an oral direct factor Xa inhibitor developed for prophylaxis and treatment of thromboembolic disorders. Laboratory monitoring is not necessary, but the effects on common coagulation reagents and assays are clinically valuable information.

AB - Apixaban is an oral direct factor Xa inhibitor developed for prophylaxis and treatment of thromboembolic disorders. Laboratory monitoring is not necessary, but the effects on common coagulation reagents and assays are clinically valuable information.

U2 - 10.1111/jth.12649

DO - 10.1111/jth.12649

M3 - Article

C2 - 24965851

SN - 1538-7933

VL - 12

SP - 1545

EP - 1553

JO - Journal of Thrombosis and Haemostasis

JF - Journal of Thrombosis and Haemostasis

IS - 9

ER -

Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-Xa assays.

Abstract

Subject classification (UKÄ)

Access to Document

Fingerprint

Cite this